UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...